EGFR and neoplasm: However, a recent study using a FAP targeted PET radioligand, [68Ga]-FAPI, was able to detect 51/51 PDAC lesions (mean SUVmax of ~ 10)32, EGFR targeting cetuximab-IRDye800 was able to detect 7/7 pancreatic lesions using NIRF imaging37, and a recent IHC study described strong ITGA5 expression in the tumor stroma of 66% out of 137 primary PDAC samples (without neoadjuvant treatment)35.